FDA Approves Trodelvy in Pre-treated HR+/HER2- Metastatic Breast Cancer
Gilead Sciences, Inc. announced the U.S. Food and Drug Administration (FDA) has approved Trodelvy (sacituzumab govitecan-hziy) for the treatment of adult patients with unresectable…
Read More...
Read More...
